We 
Introduction
Metaplastic carcinoma of the breast is a relatively rare type of breast cancer (less than 1%) that encompasses a heterogeneous group of breast carcinoma characterized by cancer cells displaying differentiation toward epithelial (squamous) or mesenchymal elements like spindle, chondroid, osseous and rhabdoid cells (1) . Cartilaginous and/or osseous metaplasias are exceptionally rare, occurring in 0.003-0.12% of cases (2, 3) . Osseous differentiation can have either benign or malignant features. Carcinoma with malignant osseous differentiation is considered to be a carcinosarcoma. When the osseous metaplasia has a malignant morphology and occupies almost the entire lesion, the microscopic diagnosis of a carcinosarcoma and the differentiation from a primary mammary sarcoma can be very difficult. We present a case of carcinosarcoma with massive osseous differentiation mimicking a primary osteosarcoma of the breast, which was also triple negative (ER, PR and Her2/neu) and positive for basal cell-type of cytokeratins and myoepithelial markers indicating that this subtype is a particular variant of tumor which should have a different treatment.
Case report
A 77-year-old woman with no history of previous breast surgery or radiotherapy was admitted to the Surgical Department for a 3cm diameter palpable mass in the superior-exterior quadrant of the left breast which was diagnosed as malignant at the intraoperatory examination. The patient underwent total mastectomy and axillary lymph node dissection. Gross examination of the specimen revealed an ill-defined solid mass of 28mm diameter, gray-to-tan in color, with patchy areas of gritty, hard tissue and on cut surface with focal hemorrhage and necrosis. No areas of phyllodes tumor have been observed within the tumor (Figure 1) .
Microscopically, the tumor was composed of a high grade osteogenic sarcoma of fibroblastic type. The tumor cells arranged in fascicles were spindle or polygonal in shape, with marked atypical nuclei and frequent mitotic figures (41 mitoses/10HPF). These areas are admixed with variable areas of osteoid formation, necrosis and hemorrhage (Figures 2, 3) . No areas of classic infiltrating ductal carcinoma were observed on careful examination of the 4 sections from the tumor; multiple ducts with high grade in situ ductal carcinoma were seen at the periphery of the tumor or entrapped within the tumor ( Figure 4A) . The tumor had pushing-type of margins at the periphery and no tumor emboli were seen adjacent to the tumor.
Immunohistochemically, the sarcomatous tumor cells were diffusely positive for Vimentin (Dako, prediluted), Osteopontin (Dako, prediluted), CD 56 (Dako, prediluted), EGFR (human epidermal growth factor receptor) (Dako, prediluted) and the ki 67 (Dako, prediluted) index was 90% but these cells were negative for ER, PR and Her2/neu (all markers Dako, prediluted) ( Figure  4B -C). They were also negative for CD 34, Synaptophisin and S-100 protein (all markers Dako, prediluted). However, the sarcomatous component was focally positive for basal cell-type cytokeratins (CK) as CK 34betaE12, CK17 and CK5/6 and diffuse positive for myoepithelial markers such as p63, Actin and CD 10 (al markers Dako, prediluted) ( Figures 4D-F , 5A-C). Those minor areas that were positive for basal-cell-type CK were also positive for AE1/AE3 and E-Cadherin (Dako, prediluted) highlighting the infiltrating carcinomatous component of ductal type, with a squamoid appearance ( Figure 5D-F) . These minor carcinomatous foci were negative for ER, PR and HER2/neu and ki67 index was 80%. Also, this second component was negative for Vimentin but focally positive for CD 10 ( Table 1) . Due to the presence of malignant mesenchymal component associated with a minor malignant epithelial component a diagnosis of high grade carcinosarcoma with basal-like and myoepithelial differentiation, associated with high grade in situ carcinoma was established. 10 axillary lymph nodes were negative for metastatic carcinoma. The patient underwent radiotherapy and 6 month after the surgery she developed multiple osseous metastases. Due to the age of the patient no other treatment was indicated and she is still alive 2 years after the initial diagnosis with metastatic disease but no sign of local recurrences.
Discussion
Metaplastic carcinoma is a general term referring to a heterogeneous group of breast tumors characterized by an intimate admixture of adenocarcinoma with dominant areas of spindle cell, squamous, osseous or chondroid differentiation (1, 4, 5) . Although the most commonly encountered heterologous elements in mammary gland are bone and cartilage, invasive breast cancer with cartilaginous or osseous metaplasia is rare, with a reported frequency of 0.003-0.12% (2, 3) . Osseous metaplasia may have either a benign pattern or a malignant one. Most of these tumors contain benign areas of bone formation within otherwise typical carcinoma; a zone of reactive stromal cells often separates the carcinoma from the bone (6). The rare examples of such tumors that have been studied in detail in electron microscopy show no evidence of epithelial transformation of the osseous component and do not express cytokeratin suggesting that these areas may develop from stromal cells (7) . The presence of areas of benign osseous differentiation does not change the prognosis of a not otherwise specified infiltrating ductal carcinoma; some of the papers reported a better prognosis of these lesions (8) .
When the areas of osseous differentiation are malignant and admixed with areas of carcinoma, a diagnosis of carcinosarcoma is recommended and this tumor should be distinguished from carcinomas displaying mature bone (9) . In carcinosarcoma the areas of malignant bone differentiation do not express epithelial markers. When these areas occupy the majority of the tumor, the microscopic diagnosis is very difficult as this lesion can be misdiagnosed as a primary sarcoma of the breast, especially with osteosarcoma. Pure primary osteogenic sarcoma of the breast is very rare, more often mammary osteosarcoma is a component of biphasic tumor such as fibroadenoma, phyllodes tumor or carcinosarcoma. In this case, no distinctive areas of infiltrating carcinoma have been noticed on H-E sections. On microscopic examination the tumor was composed only of pure osteogenic sarcoma of spindle cell type. However, the immunohistochemical analysis highlighted small areas of pan-CK (AE1/AE3) positivity as being carcinomatous areas. This, together with the presence of in situ ductal carcinoma at the periphery of the tumor allowed us a correct diagnosis of carcinosarcoma. This is the reason why, it is important that all the breast tumors with massive sarcomatous component should be evaluated on immunohistochemistry for the expression of epithelial antigens. The origin of the sarcomatous component in these tumors has been attributed to the metaplastic potential of the myoepithelial cells (9) (10) (11) . The focal positivity of both the sarcomatous and carcinomatous component in the present tumor for a variety of myoepithelial markers such as p63, CD 10, Actin in combination with positivity for basal cell-type of CK such as CK 34beta E12, CK 17, CK 5/6 confirms a myoepthelial differentiation. Also, the positivity for such markers confirms the fact that this tumor belongs to the basal-like type of breast carcinomas, same as the metaplastic carcinoma of the breast which has clinical and prognostical implications.
Carcinosarcoma represents a very aggressive tumor with a poorer prognosis than not other-72 -14) . Metaplastic breast carcinomas (including carcinosarcomas -as shown in this case) are commonly negative for HER2/neu and ER, PR which also implies that the treatment for this kind of tumor should be different. These patients should not receive endocrine agents or HER2/neu therapy but a multimodality approach including sarcoma-directed adjuvant chemotherapy and radiotherapy (1, (15) (16) (17) (18) . Also, carcinosarcoma (this case included) as most of the metaplastic carcinomas overexpress EGFR and these patients might benefit from therapies targeting EGFR such as gefitinib and cetuximab (19) .
